This Article  • Abstract  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (42)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Panic Disorder  • Alert me on articles by topic  Social Bookmarking   What's this?

Induced Panic Attacks Shift -Aminobutyric Acid Type A Receptor Modulatory Neuroactive Steroid Composition in Patients With Panic Disorder

Preliminary Results

Andreas Ströhle, MD; Elena Romeo, MD; Flavia di Michele, MD; Augusto Pasini, MD; Bettina Hermann, PhD; Gisela Gajewsky; Florian Holsboer, MD, PhD; Rainer Rupprecht, MD

Arch Gen Psychiatry. 2003;60:161-168.

ABSTRACT
Background  Certain metabolites of progesterone such as 3,5-tetrahydroprogesterone (3,5-THP; allopregnanolone) and 3,5-THP (pregnanolone) are potent, positive allosteric modulators of -aminobutyric acid type A receptors. Although animal studies suggest anxiolytic properties of these endogenous modulators of central nervous excitability, no clinical data indicate whether they are also involved in the pathophysiology of anxiety disorders and panic attacks.

Methods  We quantified the concentrations of 3,5-THP, 3,5-THP, the isomer 3,5-THP, and their precursors in the plasma of 10 patients with panic disorder and matched control subjects during panic attacks induced by means of sodium lactate and cholecystokinin tetrapeptide administration, using a highly sensitive gas chromatography–mass spectrometry analysis.

Results  Panic attacks induced by sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder were accompanied by pronounced decreases in the concentrations of 3,5-THP and 3,5-THP and a concomitant increase in the concentrations of the functional antagonistic isomer 3,5-THP, findings that are compatible with a decreased -aminobutyric acid–ergic tone. No changes in neuroactive steroid concentrations were observed after placebo administration in patients with panic disorder or after placebo, sodium lactate, or cholecystokinin tetrapeptide administration in controls.

Conclusions  The association between changes in plasma neuroactive steroid concentrations and experimentally induced panic attacks and the well-documented pharmacological properties of these compounds as -aminobutyric acid type A receptor modulators suggest that neuroactive steroids may play a role in the pathophysiology of panic attacks in patients with panic disorder.

INTRODUCTION

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

THE SPONTANEOUS panic attack is the key feature of panic disorder, which has a prevalence of 1% to 2%.^1-2 This anxiety disorder is associated with pervasive social and health consequences similar to or greater than those associated with major depression.³ Serotonergic, noradrenergic, -aminobutyric acid (GABA)–ergic and respiratory system abnormalities in panic disorder have been described during panicogenic challenge paradigms.^4-6 The use of these behavioral challenges in panic disorder is unique in psychiatric research in that the leading clinical phenomenon, the panic attack, can be provoked and quantified in a laboratory setting. Although cholecystokinin tetrapeptide (CCK-4) has respiratory effects as well,⁷ it activates the hypothalamic-pituitary-adrenocortical system,^8-10 unlike sodium lactate^11-12 and carbon dioxide.^{6, 13} Although various attempts have been made to delineate the neurobiological determinants of panic anxiety,^4-6 no conclusive model of the abnormally sensitive fear network and anxiety modulation in panic disorder has been established.

In the last decade, evidence has emerged that certain derivatives of progesterone, the so-called neuroactive steroids, may modulate neuronal excitability through rapid nongenomic effects at the cell surface.^14-16 For instance, the 3-reduced metabolites of progesterone such as 3,5-tetrahydroprogesterone (3,5-THP; allopregnanolone) and 3,5-THP (pregnanolone) are potent positive allosteric modulators of GABA_A receptors, whereas the stereoisomer 3,5-THP may act as a functional antagonist for GABA_A-agonistic steroids.^14-15,17-18 Progesterone is formed from pregnenolone by the 3-hydroxysteroid dehydrogenase/⁵-⁴-isomerase. The 5-reductase catalyses the reduction of progesterone into the 5-pregnane steroid 5-dihydroprogesterone (5-DHP); the 5-reductase reduces progesterone to 5-DHP. These reactions are irreversible in mammalian cells.¹⁹ These pregnane steroids can be further reduced to the neuroactive steroids 3,5-THP and 3,5-THP by the 3-hydroxysteroid oxidoreductase.^20-21 This reaction may work in the reductive and oxidative directions, depending on the cofactors present in the environment.^{15, 22-23} A detailed review of steroidogenic enzymes is available elsewhere.²³ Although neuroactive steroids may be synthesized in the brain without the aid of peripheral sources, and although plasma concentrations of neuroactive steroids do not necessarily parallel brain concentrations,^24-25 a correlation between plasma and brain concentrations of neuroactive steroids has been shown under various experimental conditions.^26-28

We now have evidence of a disturbed equilibrium of endogenous neuroactive steroids in patients with premenstrual syndrome²⁹ and major depression, with reduced concentrations of GABA-agonistic steroids that can be corrected by antidepressant treatment.^30-33 Although animal studies suggest a pronounced anxiolytic effect of 3-reduced neuroactive steroids,^34-35 recent evidence showed that baseline concentrations of these neuroactive steroids are increased in panic disorder,³⁶ which is the opposite of the steroid composition seen in depression. However, data on neuroactive steroids during panic attacks in humans are not available. Because experimentally induced panic in patients with panic disorder is the best established laboratory model of pathological anxiety in humans, we studied the plasma concentrations of GABA_A receptor–modulating neuroactive steroids and their precursors in patients with panic disorder and healthy control subjects during a sodium lactate and a CCK-4 challenge. If neuroactive steroids are involved in the pathophysiology of panic attacks, changes in the levels and composition of neuroactive steroids might be expected.

METHODS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

SUBJECTS

We studied 10 patients (3 women and 7 men; mean age, 36.3 years; SD, 2.6 years) with a diagnosis of panic disorder but without a comorbid Axis I disorder as assessed with the Structured Clinical Interview for DSM-IV.³⁷ We found no lifetime history of a major depressive episode. The mean age of onset of the panic disorder was 26.0 years (SD, 4.9 years). The Panic and Agoraphobia Scale³⁸ indicated a moderate severity of panic and agoraphobia (mean score, 21.7; SD, 9.41). The mean Hamilton Depression Scale³⁹ score was 6.9 (SD, 3.5) and mean Hamilton Anxiety Scale⁴⁰ score was 12.5 (SD, 6.1), indicating low depression and moderate anxiety in the patients. Clinical Global Impression⁴¹ scores indicated a moderate illness severity (mean, 4.8; SD, 1.0). Mean severity of agoraphobia⁴² alone was 56.2 (SD, 24.2), and mean severity of accompanied agoraphobia was 46.7 (SD, 22.5). Patients experienced a mean frequency of panic attacks of 3.8 per week (SD, 1.0). Six of the 10 patients were drug naive. Of the other patients, 1 patient received moclobemide, 600 mg/d, until 4 weeks before the study and 1 patient received buspirone hydrochloride, 30 mg/d; 1, doxepin hydrochloride, 12.5 mg/d; and 1, opipramol hydrochloride, 25 mg/d until 10 days before the study. Ten healthy age- and sex-matched controls with no personal or family history of a psychiatric disorder were also recruited for the study. Women were matched for menstrual status; 1 patient and 1 control were in the luteal and 2 patients and 2 controls were in the follicular phase of the menstrual cycle. Subjects had undergone a thorough medical examination, including urine toxicologic tests to rule out other illnesses, drug intake, and lifestyles that could interfere with the study. The protocol was approved by the Ethics Committee for Human Experiments at Ludwig Maximilian University, Munich, Germany. After a complete description of the study to the subjects, we obtained written informed consent.

STUDY DESIGN

All subjects underwent studies in a supine position in a soundproof room with a single bed from 9 AM to 1 PM. In a double-blind randomized design, each subject received an intravenous infusion (10 mL/kg body weight) of 0.5M sodium lactate from 11 to 11:20 AM, 0.9% isotonic sodium chloride solution from 11 to 11:20 AM with a 25-µg CCK-4 bolus (Clinalfa; Laufelfingen, Switzerland) at 11 AM (10 mL injected within 1 minute), or 0.9% isotonic sodium chloride solution alone (placebo condition) for 20 minutes from 11 to 11:20 AM on separate days with at least 2 days between experimental conditions. The Acute Panic Inventory (API)⁴³ was administered at 11:00 (baseline), 11:05, 11:10, 11:20, and 11:30 AM and noon by a rater masked to the procedure; the maximum intensity during the observation period was noted. Visual analog scales for anxiety and arousal were administered at the same times. The occurrence of a panic attack was defined as an API total score exceeding 20 and an increment of at least 14 points above the preinfusion score.^{10, 43}

NEUROACTIVE STEROID DETERMINATIONS

Blood samples were taken at 11:00 (baseline), 11:05, 11:10, 11:20, and 11:30 AM and noon and quantified for levels of progesterone, 5-DHP (5-pregnan-3,20-dione), 5-DHP (5-pregnan-3,20-dione), 3,5-THP (5-pregnan-3-ol-20-one), 3,5-THP (5-pregnan-3-ol-20-one), and 3,5-THP (5-pregnan-3-ol-20-one) by means of a highly sensitive combined gas chromatography–mass spectrometry (GC-MS) analysis.^{30, 44} The plasma volume used for analysis was 1 mL. Tritiated progesterone was the internal standard to monitor the extraction procedure. For GC-MS determinations, we used 10 pmol of progesterone as an internal standard to quantify the 3,5-THP enantiomers and 20 pmol of 3,5-THP to quantify the other steroids. After extraction with 3 x 2 mL of ethyl acetate and separation by means of thin-layer chromatography (ie, carbon tetrachloride/methanol [vol/vol, 99:1], and cyclohexane/ethyl acetate [vol/vol/3:2]), the eluate containing 3,5-THP, 3,5-THP, 3,5-THP, and progesterone was lyophilized and derivatized with heptafluorobutyric acid anhydride. We derivatized 5-DHP and 5-DHP with 2% methoxamine hydrochloride in pyridine. A Finningham GC-MS equipped with a capillary column was used to analyze the derivatized steroids in the negative-ion chemical ionization mode, in the single-ion monitoring. The detection limit was approximately 10 fmol. All neuroactive steroid concentrations are given as mean ± SEM.

STATISTICAL ANALYSIS

To test for statistical significance of treatment (isotonic sodium chloride solution, sodium lactate, and CCK-4), disease (panic disorder), and efficacy duration (time) on the neuroactive steroid concentrations, we performed a 3-factorial multivariate analysis of variance with a repeated-measures design. Treatment and time were 2 within-subjects factors, with 3 and 6 levels, respectively. Group (patient or control) was the between-subjects factor with 2 levels. When significant main or interaction effects were found, we identified steroids that contributed significantly to these effects by means of subsequent univariate F tests. For the steroids that showed a significant time and/or treatment effect, we also performed tests with contrasts to locate pairs of time points or treatments with significant mean differences. To neutralize the carryover effects of baseline differences between the treatments and groups, steroid concentrations at all times were normalized (divided by the mean baseline value) for each treatment and each group. To approach normality and homogeneity, we further transformed the normed data with the artan transformation (x* = artan[x]; in which the asterisk indicates x after transformation) before they were supplied to the multivariate analysis of variance. In addition, we applied the Fisher exact test to test for group differences in panic attack frequency. We accepted = .05 as a nominal level of significance. To keep the type I error at no greater than 0.05, we performed all post hoc tests (tests with contrasts) at a reduced level of significance (adjusted according to the Bonferroni procedure). To further characterize the relationship of time-dependent changes between psychopathological parameters and neuroactive steroid concentrations, we performed cross-correlation analysis.

RESULTS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

BEHAVIORAL CHANGES

According to formal criteria for panic attacks,⁴³ 9 sodium lactate– and 8 CCK-4–induced attacks were experienced among the 10 patients diagnosed as having panic disorder. Although the maximum change in psychopathology after CCK-4 administration was found shortly after peptide administration, sodium lactate–induced changes peaked at 11:20 AM (Figure 1). Changes in the API scores of controls also indicated the occurrence of paniclike attacks in 3 subjects during sodium lactate administration and 2 subjects after CCK-4 administration. Fisher exact test underscored a higher frequency of experimentally induced panic attacks in patients with panic disorder compared with controls (>0.60; P = .02). Changes in the API scores were paralleled by changes in anxiety and arousal visual analog scale scores in patients and controls (data not shown).

View larger version (20K): [in this window] [in a new window] Figure 1. Behavioral effects of sodium lactate, cholecystokinin tetrapeptide (CCK-4), and isotonic sodium chloride solution (placebo) on the Acute Panic Inventory (API) score in patients with panic disorder (A) and control subjects (B). Scores are given as mean ± SEM. Times are depicted in the morning and at noon.

NEUROACTIVE STEROID CONCENTRATIONS

Multivariate analysis of variance with the transformed data showed highly significant main effects and interactions for the concentrations of the neuroactive steroids studied (effect of group, F_6,13 = 11.88 [P<.001]; effect of treatment, F_12,62 = 8.76 [P<.001]; effect of group x treatment, F_12,62 = 6.99 [P<.001]; effect of time, F_30,342 = 7.76 [P<.001]; effect of group x time, F_30,342 = 7.18 [P<.001]; effect of treatment x time, F_60,921 = 4.93 [P<.001]; and effect of group x treatment x time, F_60,921 = 4.76 [P<.001] [Wilks averaged multivariate analysis of variance]). Univariate F tests indicate that the interaction of group x treatment x time is significant for 3,5-THP (F_10,180 = 15.66 [P<.001]), 3,5-THP (F_10,180 = 13.35 [P<.001]), 3,5-THP (F_10,180 = 9.52 [P<.001]), 5-DHP (F_10,180 = 14.19 [P<.001]), and 5-DHP (F_10,180 = 3.60 [P<.001]). Progesterone concentrations were not influenced by the factors or their interactions.

Therefore, we analyzed for all steroid levels except progesterone the simple effects (ie, changes compared with baseline) in the 3 treatment conditions of patients and controls. We found that in patients with panic disorder, 3,5-THP concentrations were decreased from 11:05 AM to noon in the CCK-4 condition and from 11:10 AM to noon in the sodium lactate condition (tests with contrasts, P<.05). Furthermore, 3,5-THP concentrations were decreased from 11:10 AM until noon after CCK-4 administration and from 11:20 AM to noon after sodium lactate administration (tests with contrasts, P<.05). Concomitantly, 3,5-THP concentrations increased from 11:05 AM to noon in the CCK-4 condition, and from 11:20 AM to noon in the sodium lactate condition (tests with contrasts, P<.05). After sodium lactate and CCK-4 administration, 5-DHP concentrations were decreased from 11:10 AM to noon in patients with panic disorder (tests with contrasts, P<.05). Compared with baseline, CCK-4 administration increased 5-DHP concentrations at 11:20 AM, whereas sodium lactate administraion increased 5-DHP concentrations between 11:10 and 11:30 AM (tests with contrasts, P<.05) (Figure 2). Individual concentrations of 3,5-THP and 3,5-THP in the patients with panic disorder are presented in Table 1. Changes in neuroactive steroid concentrations after CCK-4 or sodium lactate administration are similar in female and male patients with panic disorder.

View larger version (46K): [in this window] [in a new window] Figure 2. Effects of sodium lactate, cholecystokinin tetrapeptide (CCK-4), and isotonic sodium chloride solution (placebo) on the concentrations of neuroactive steroids and their precursors, including progesterone (A); 5-dihydroprogesterone (DHP) (B); 5-DHP (C); 3,5-tetrahydroprogesterone (THP) (D); 3,5-THP (E); and 3,5-THP (F) in patients with panic disorder. Scores are given as mean ± SEM. Times are depicted in the morning and at noon. To convert nanomoles per liter to nanograms per milliliter, divide progesterone data by 3.18; 3,5-THP, 3,5-THP, and 3,5-THP data by 3.14; and 5-DHP and 5-DHP data by 3.16. Asterisk indicates P<.05, sodium lactate vs baseline; dagger, CCK-4 vs baseline.

View this table: [in this window] [in a new window] Individual Neuroactive Steroid Concentrations in Patients With Panic Disorder at Baseline and During Sodium Lactate and CCK-4 Challenge*

Neuroactive steroid concentrations did not change in patients with panic disorder receiving placebo or in controls receiving placebo, sodium lactate, or CCK-4 (Figure 2 and Figure 3). Even in those controls with a paniclike attack after sodium lactate (n = 3) or CCK-4 (n = 2) administration, no major changes of neuroactive steroid concentrations could be observed that were comparable to the changes observed in patients with panic disorder (data not shown).

View larger version (36K): [in this window] [in a new window] Figure 3. Effects of sodium lactate, cholecystokinin tetrapeptide (CCK-4), and isotonic sodium chloride solution (placebo) on the concentrations of neuroactive steroids and their precursors, including progesterone (A); 5-dihydroprogesterone (DHP) (B); 5-DHP (C); 3,5-tetrahydroprogesterone (THP) (D); 3,5-THP (E); and 3,5-THP (F) in healthy control subjects. Scores are given as mean ± SEM. Times are depicted in the morning and at noon. To convert nanomoles per liter to nanograms per milliliter, divide progesterone data by 3.18; 3,5-THP, 3,5-THP, and 3,5-THP data by 3.14; and 5-DHP and 5-DHP data by 3.16.

CROSS-CORRELATION ANALYSIS

Cross-correlation analysis between the course of the mean neuroactive steroid concentrations and the mean API or anxiety and arousal visual analog scale scores in the patients from 11:00 AM and noon showed significant correlations by lag +1 for the CCK-4 condition (r>0.76; P<.05), indicating that the API or visual analog scale scores from 11:00 AM point to a simultaneous course of the neuroactive steroid concentrations from 11:05 AM. In the sodium lactate condition, we found significant correlations at lag 0 (r>0.76; P<.05), indicating an almost parallel course of the changes in neuroactive steroid concentrations and the degree (severity) of panic anxiety at each time point from 11:00 AM to noon.

COMMENT

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

During experimentally induced panic attacks in patients with panic disorder, we found a pronounced decrease in the concentrations of 3,5-THP (to 4% of baseline) and 3,5-THP (to 25% of baseline), which are positive allosteric modulators of GABA_A receptors, and a concomitant increase in 3,5-THP (to 500% of baseline), which may act as a functional antagonist for GABA-agonistic steroids.^14-15,17-18 Although progesterone concentrations were not changed, 5-DHP concentrations were decreased and 5-DHP concentrations were increased. No changes could be observed after placebo administration in patients with panic disorder or after placebo, sodium lactate, or CCK-4 administration in controls. Thus, the short-term changes in neuroactive steroid concentrations somehow parallel psychopathological changes during experimentally induced panic attacks of patients.

Although plasma concentrations of neuroactive steroids do not necessarily correlate with brain concentrations,²⁴ and although differences with regard to the time course of changes in neuroactive steroid concentrations have been reported,^26-27 several animal studies describe a relationship between plasma and brain steroid concentrations.^26-28 Moreover, selective serotonin reuptake inhibitors such as fluoxetine have been shown to affect plasma³⁰ and cerebrospinal fluid³¹ steroid concentrations in a similar manner. Thus, changes in plasma steroid concentrations may reflect brain concentrations to a certain extent. However, extrapolations from plasma steroid concentrations to neuronal function should be made with caution, given these limitations. Nevertheless, our findings are compatible with the hypothesis that the induction of panic attacks in patients with panic disorder alters progesterone metabolism in a direction that may result in decreased GABA_A receptor–mediated neuronal activity. The GABA_A receptors have been shown to be modulated by neuroactive steroids in the nanomolar concentration range.⁴⁵ Because brain concentrations of neuroactive steroids usually exceed plasma concentrations,^{15, 46} it is conceivable that if similar changes occur in the brain, the pronounced changes in neuroactive steroid levels during induced panic attacks result in a decreased neuronal response to endogenous GABA. A primarily pharmacological effect of CCK-4 or sodium lactate on the concentrations of neuroactive steroids is unlikely because of the lack of effect in healthy controls.

Preclinical studies already have suggested the anxiolytic properties of neuroactive steroids.^34-35 Moreover, sleep studies have showed benzodiazepinelike effects of 3,5-THP⁴⁶ and progesterone on sleep in rats⁴⁷ and humans.⁴⁸ Although cerebrospinal fluid and plasma GABA concentrations are not changed in panic disorder,^49-50 patients have been reported to be less sensitive to the effects of benzodiazepines.^51-52 Furthermore, the effectiveness of high-potency benzodiazepines in blocking panic attacks⁵³ and results of neuroimaging studies^54-56 provide evidence of changes in benzodiazepine-GABA_A receptor function in panic disorder. Thus, our results are compatible with the hypothesis of a panic/anxiety–associated failure in patients with panic disorder to regulate the synthesis and/or catabolism of neuroactive steroids modulating GABA_A receptors. This appears to be somehow related to the etiology of panic disorder, as such changes were absent even in those controls who experienced a paniclike attack after sodium lactate or CCK-4 administration. Future studies are needed to clarify whether changes in neuroactive steroid concentrations contribute to the occurrence of panic attacks in patients with panic disorder or whether they are a consequence of them. As panic attacks induced by sodium lactate and CCK-4 elicited comparable changes in neuroactive steroid homeostasis, these alterations in the concentrations of neuroactive steroids appear to be a general feature of panic attacks, irrespective of the use of distinct challenges. Moreover, our findings are not likely a stress phenomenon, since stress elicited in experimental animals by means of carbon dioxide administration⁵⁷ or forced swimming^58-59 has been shown to increase 3-reduced neuroactive steroid levels. In view of the anxiolytic effects of 3-reduced neuroactive steroids in preclinical studies,^34-35 these endogenous modulators of GABA_A receptor function or drugs that interfere with their levels might constitute a new class of drugs for the treatment of panic disorder. Because long-term antidepressant treatment has been shown to influence the composition of neuroactive steroids contrary to panic anxiety–induced changes,^30-33 the antipanic efficacy of antidepressants in the treatment of panic disorder may in part be mediated by stabilizing the equilibrium of endogenous neuroactive steroid concentrations.

CONCLUSIONS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

Our data suggest that a dysregulation of neuroactive steroids that target GABA_A receptors may contribute to the occurrence of experimentally induced panic attacks in patients with panic disorder. Whether similar changes of neuroactive steroids occur during spontaneous panic attacks remains to be investigated. Nevertheless, our findings suggest that neuroactive steroid modulation may be a promising new strategy for the treatment of anxiety disorders such as panic disorder.

AUTHOR INFORMATION 

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

Corresponding author and reprints: Andreas Ströhle, MD, Department of Psychiatry and Psychotherapy, Charité Hospital, Humboldt University at Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany (e-mail: andreas.stroehle{at}charite.de).

Submitted for publication December 11, 2000; final revision received May 23, 2002; accepted June 15, 2002.

This study was supported by the Gerhard Hess Program of the Deutsche Forschungsgemeinschaft, Bonn, Germany (Dr Rupprecht).

We thank Alexander Yassouridis, PhD, for statistical advice.

From the Max Planck Institute of Psychiatry, Munich, Germany (Drs Ströhle, Hermann, Holsboer, and Rupprecht and Ms Gajewsky); and Tor Vergata University, IRCCS Santa Lucia, Rome, Italy (Drs Romeo, di Michele, and Pasini). Dr Ströhle is now with the Department of Psychiatry and Psychotherapy, Charité Hospital, Humboldt University at Berlin, Berlin, Germany.

REFERENCES

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Conclusions  • Author information   • References

1. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakleybrowne MA, Rubiostipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry. 1997;54:305-309. FREE FULL TEXT 2. Katerndahl DA, Realini JP. Lifetime prevalence of panic states. Am J Psychiatry. 1993;150:246-249. FREE FULL TEXT 3. Markowitz JS, Weissman MM, Ouelette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psychiatry. 1989;46:984-992. FREE FULL TEXT 4. Gorman JM, Liebowitz MR, Fyer AJ, Stein J. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry. 1989;146:148-161. FREE FULL TEXT 5. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157:493-505. FREE FULL TEXT 6. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. Arch Gen Psychiatry. 1993;50:306-317. FREE FULL TEXT 7. Bradwejn J, Koszycki D. Comparison of the panicogenic effects of cholecystokinin 30-33 and carbon dioxide in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:237-239. PUBMED 8. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings. Arch Gen Psychiatry. 1989;46:511-517. FREE FULL TEXT 9. Kellner M, Yassouridis A, Jahn H, Wiedemann K. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetratpeptide in patients with panic disorder. Psychopharmacology (Berl). 1997;133:55-61. FULL TEXT | PUBMED 10. Ströhle A, Holsboer F, Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide–induced panic attacks in patients with panic disorder. Neuropsychopharmacology. 2000;22:251-256. FULL TEXT | ISI | PUBMED 11. Pitts FM, McClure JN. Lactate metabolism in anxiety neurosis. N Engl J Med. 1967;177:1329-1336. 12. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, Appleby IL, Anderson S, Palij S, Davies SO, Klein DF. Lactate provocation of panic attacks, II: biochemical and physiological findings. Arch Gen Psychiatry. 1985;42:709-719. FREE FULL TEXT 13. Gorman JM, Fyer MR, Goetz R, Askanazi J, Liebowitz MR, Fyer AJ, Kinney J, Klein DF. Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry. 1988;45:31-39. FREE FULL TEXT 14. Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992;6:2311-2322. ABSTRACT 15. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999;22:410-416. FULL TEXT | ISI | PUBMED 16. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004-1007. FREE FULL TEXT 17. Prince RJ, Simmonds MA. 5-Pregnan-3-ol-20-one, a specific antagonist at the neurosteroid site of the GABA_A receptor complex. Neurosci Lett. 1992;135:273-275. FULL TEXT | ISI | PUBMED 18. Maitra R, Reynolds JN. Modulation of GABA(A) receptor function by neuroactive steroids: evidence for heterogeneity of steroid sensitivity of recombinant GABA(A) receptor. Can J Physiol Pharmacol. 1998;76:909-920. FULL TEXT | ISI | PUBMED 19. Celotti F, Melcangi RC, Martini L. The 5-reductase in the brain: molecular aspects and relation to brain function. Front Neuroendocrinol. 1992;13:163-215. ISI | PUBMED 20. Campbell JS, Karavolas HJ. Characterization of the purified pituitary cytosolic NADPH:5 -dihydroprogestrone 3 -hydroxysteroid oxidoreductase. J Steroid Biochem Mol Biol. 1990;37:535-543. FULL TEXT | ISI | PUBMED 21. Krause JE, Karavolas HJ. Pituitary 5-dihydroprogesterone 3-hydroxysteroid oxidoreductases. J Biol Chem. 1980;255:11807-11814. FREE FULL TEXT 22. Karavolas HJ, Hodges D. Neuroendocrine metabolism of progesterone and related progestin steroids and neuronal activity. Ciba Found Symp. 1990;153:22-55. PUBMED 23. Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol. 2000;21:1-56. FULL TEXT | ISI | PUBMED 24. Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci U S A. 1996;93:12599-12604. FREE FULL TEXT 25. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3-alpha,5-alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry. 1998;44:865-873. FULL TEXT | ISI | PUBMED 26. Concas A, Mostallino PC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M, Purdy RH, Grisenti P, Biggio G. Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci U S A. 1998;95:13284-13289. FREE FULL TEXT 27. Morrow AL, Janis GC, VanDoren MJ, Matthews DB, Samson HH, Janak PH, Grant KA. Neurosteroids mediate pharmacological effects of ethanol: a new mechanism of ethanol action? Alcohol Clin Exp Res. 1999;23:1933-1940. FULL TEXT | ISI | PUBMED 28. Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry. 2000;47:1000-1004. FULL TEXT | ISI | PUBMED 29. Wang M, Seippel L, Purdy RH, Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5-pregnane-3,20-dione and 3-hydroxy-5-pregnan-20-one. J Clin Endocrinol Metab. 1996;81:1076-1082. ABSTRACT 30. Romeo E, Ströhle A, di Michele F, Spaletta G, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry. 1998;155:910-913. FREE FULL TEXT 31. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998;95:3239-3244. FREE FULL TEXT 32. Ströhle A, Romeo E, Hermann B, di Michele F, Spaletta G, Pasini A, Holsboer F, Rupprecht R. Concentrations of 3-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry. 1999;45:274-277. FULL TEXT | ISI | PUBMED 33. Ströhle A, Pasini A, Romeo E, Hermann B, Spalletta G, di Michele F, Holsboer F, Rupprecht R. Fluoxetine decreases concentrations of 3,5-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res. 2000;34:183-186. FULL TEXT | ISI | PUBMED 34. Bitran D, Hilvers RJ, Kellog CK. Anxiolytic effects of 3-hydroxy-5[]-pregnan-20-one: endogenous metabolites that are active at the GABA_A receptor. Brain Res. 1991;561:157-161. FULL TEXT | ISI | PUBMED 35. Patchev VK, Shoaib M, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience. 1994;62:265-271. FULL TEXT | ISI | PUBMED 36. Ströhle A, Romeo E, di Michele F, Pasini A, Yassouridis A, Holsboer F, Rupprecht R. GABA_A receptor–modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry. 2002;159:145-147. FREE FULL TEXT 37. Wittchen H-U, Wunderlich U, Gruschwitz S, Zaudig M. SKID-I: Strukturiertes klinisches Interview für DSM-IV. Göttingen, Germany: Hogrefe; 1997. 38. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia, II: the Panic and Agoraphobia Scale. Int Clin Psychopharmacol. 1995;10:73-81. 39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. 40. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55. ISI | PUBMED 41. National Institute of Mental Health. Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery. Chevy Chase, Md: National Institute of Mental Health; 1976:12-1–12-6. 42. Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The mobility inventory for agoraphobia. Behav Res Ther. 1985;23:35-44. FULL TEXT | ISI | PUBMED 43. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF. Measurement of lactate-induced panic and anxiety. Psychiatry Res. 1987;20:97-105. FULL TEXT | ISI | PUBMED 44. Romeo E, Cheney DL, Zivkovic I, Costa E, Guidotti A. Mitochondrial diazepam-binding inhibitor receptor complex agonists antagonize dizocilpine amnesia: putative role for allopregnanolone. J Pharmacol Exp Ther. 1994;270:89-96. FREE FULL TEXT 45. Lambert JJ, Belelli D, Hillvenning C, Peters JA. Neurosteroids and GABA(A) receptor function. Trends Pharmacol Sci. 1995;16:295-303. FULL TEXT | PUBMED 46. Lancel M, Faulhaber J, Schiffelholz T, Romeo E, di Michele F, Holsboer F, Rupprecht R. Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther. 1997;282:1213-1218. FREE FULL TEXT 47. Lancel M, Faulhaber J, Holsboer F, Rupprecht R. Progesterone induces changes in sleep EEG comparable to those of agonistic GABA_A receptor modulators. Am J Physiol. 1996;271:E763-E772. 48. Friess E, Tagaya H, Trachsel L, Holsboer F, Rupprecht R. Progesterone-induced changes in sleep in male subjects. Am J Physiol. 1997;272:E885-E891. 49. Rimón R, Lepola U, Jolkonen J, Halonen T, Riekkinen P. Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. Biol Psychiatry. 1995;38:737-741. FULL TEXT | ISI | PUBMED 50. Goddard AW, Narayan M, Woods SW, Germine M, Kramer GL, Davis LL, Petty F. Plasma levels of gamma-aminobutyric acid in panic disorder. Psychiatry Res. 1996;63:223-225. FULL TEXT | ISI | PUBMED 51. Roy-Byrne PP, Lewis N, Villacres E, Diem H, Greenblatt DJ, Shader RI, Veith R. Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry. 1989;26:744-748. FULL TEXT | ISI | PUBMED 52. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry. 1990;47:534-538. FREE FULL TEXT 53. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:413-422. FREE FULL TEXT 54. Schlegel S, Steiner H, Bokisch A, Hahn K, Schlosser R, Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by iomazenil SPECT: a preliminary report. Eur Arch Psychiatry Clin Neurosci. 1994;244:49-51. FULL TEXT | ISI | PUBMED 55. Malizia A, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA_A-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715-720. FREE FULL TEXT 56. Goddard AW, Mason GF, Almai A, Rothman DL, Nehar KL, Petroff OAC, Charney DS, Krystal JH. Reductions in occipital cortex GABA levels in panic disorder detected by ¹H-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556-561. FREE FULL TEXT 57. Barbaccia ML, Roscetti G, Trabucchi M, Mostallino MC, Concas A, Purdy RH, Biggio G. Time-dependent changes in rat brain neuroactive steroid concentrations and GABA_A receptor function after acute stress. Neuroendocrinology. 1996;63:166-172. ISI | PUBMED 58. Purdy RH, Morrow AL, Moore PH, Paul SM. Stress-induced elevations of gamma-aminobutyric acid type A receptor–active steroids in the rat brain. Proc Natl Acad Sci U S A. 1991;88:4553-4557. FREE FULL TEXT 59. Hermann B, Landgraf R, Keck ME, Wigger A, Morrow AL, Ströhle A, Holsboer F, Rupprecht R. Pharmacological characterization of cortical -aminobutyric acid type A (GABA_A) receptors in two Wistar rat lines selectively bred for high and low anxiety-related behaviour. World J Biol Psychiatry. 2000;1:137-143. PUBMED

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Altered Cerebral {gamma}-Aminobutyric Acid Type A-Benzodiazepine Receptor Binding in Panic Disorder Determined by [11C]Flumazenil Positron Emission Tomography
Hasler et al.
Arch Gen Psychiatry 2008;65:1166-1175.
ABSTRACT | FULL TEXT  

Role of Microsomal Retinol/Sterol Dehydrogenase-Like Short-Chain Dehydrogenases/Reductases in the Oxidation and Epimerization of 3{alpha}-Hydroxysteroids in Human Tissues
Belyaeva et al.
Endocrinology 2007;148:2148-2156.
ABSTRACT | FULL TEXT  

Angiotensin-II Is a Putative Neurotransmitter in Lactate-Induced Panic-Like Responses in Rats with Disruption of GABAergic Inhibition in the Dorsomedial Hypothalamus
Shekhar et al.
J. Neurosci. 2006;26:9205-9215.
ABSTRACT | FULL TEXT  

The Acute Antipanic Activity of Aerobic Exercise
Strohle et al.
Am. J. Psychiatry 2005;162:2376-2378.
ABSTRACT | FULL TEXT